| Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma C Melani, R Lakhotia, S Pittaluga, JD Phelan, DW Huang, G Wright, ... New England Journal of Medicine 390 (23), 2143-2155, 2024 | 1 | 2024 |
| Abstract PO-007: A phase 1 study of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies M Gordon, M Miljkovic, S Ng, R Lakhotia, C Melani, K Conlon, J Phelan, ... Blood Cancer Discovery 5 (3_Supplement), PO-007-PO-007, 2024 | | 2024 |
| Histopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma Y Ding, ES Jaffe Journal of Clinical and Translational Pathology, 0-0, 2024 | | 2024 |
| Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces E Apaydin Arikan, ES Jaffe Blood 143 (22), 2337-2337, 2024 | | 2024 |
| Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study LK Hilton, B Collinge, S Ben-Neriah, W Alduaij, H Shaalan, AP Weng, ... Blood, 2024 | | 2024 |
| Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK‐negative KA Ganapathi, A Nicolae, C Egan, H Geng, L Xi, SD Pack, JR McFadden, ... British Journal of Haematology 204 (5), 1862-1871, 2024 | | 2024 |
| Primary Large B-cell Lymphomas of Immune-Privileged Sites M Roschewski, JD Phelan, ES Jaffe Blood, 2024 | | 2024 |
| B-and T-/NK-Cell Lymphomas in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms and Comparison with the WHO Fifth Edition ES Jaffe, A Carbone Hemato 5 (2), 157-170, 2024 | 1 | 2024 |
| Tissue Eosinophilia in B-cell Lymphoma: An Underrecognized Phenomenon T Zhou, HW Wang, SB Ng, T Summers, L Xi, M Raffeld, S Pittaluga, ... The American Journal of Surgical Pathology 48 (4), 426-436, 2024 | | 2024 |
| Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients AJ Radtke, E Postovalova, A Varlamova, A Bagaev, M Sorokina, ... Cancer cell 42 (3), 444-463. e10, 2024 | 1 | 2024 |
| Phase Ib/II study of multi-targeted therapy with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) diffuse large B-cell … C Melani, R Lakhotia, S Pittaluga, JD Phelan, G Wright, J Simard, ... Blood 142, 434, 2023 | 4 | 2023 |
| Phase I study of response-adapted treatment with venetoclax, obinutuzumab, and magrolimab (Venom) in relapsed and refractory indolent B-cell Malignancies R Lakhotia, C Melani, S Pittaluga, JD Phelan, A Pradhan, A Tadese, ... Blood 142, 6172, 2023 | 1 | 2023 |
| Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma J Simard, JD Phelan, C Melani, R Lakhotia, S Pittaluga, JR Muppidi, ... Blood 142, 854, 2023 | 1 | 2023 |
| Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach C Amador, DD Weisenburger, A Gomez, A Bouska, F Vega, JR Cook, ... Blood 142, 1636, 2023 | | 2023 |
| Nivolumab in Lymphomatoid Granulomatosis (LYG) and Other Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPDs) and Non-Hodgkin Lymphomas (NHLs) with Systemic … D Dalela, R Lakhotia, S Pittaluga, JR Muppidi, JD Phelan, A Pradhan, ... Blood 142, 4408, 2023 | | 2023 |
| Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An LLMPP Study AL Feldman, S Dasari, LM Rimsza, DW Scott, N Oishi, C Amador, ... Blood 142, 847, 2023 | | 2023 |
| Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma R Lakhotia, C Melani, JR Muppidi, S Pittaluga, JD Phelan, C Ramsower, ... Blood 142, 1676, 2023 | | 2023 |
| Evolution of Lymphoma Diagnosis in the Era of Personalized Medicine–A Marriage of Pathology and Genomics for Clinical Practice ES Jaffe The American Journal of Pathology, 2023 | | 2023 |
| POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL) R Lakhotia, S Pittaluga, J Phelan, Y Yang, T Davies-Hill, J Simard, ... Clinical Lymphoma Myeloma and Leukemia 23, S212, 2023 | | 2023 |
| POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma J Simard, JD Phelan, C Melani, R Lakhotia, S Pittaluga, JR Muppidi, ... Clinical Lymphoma Myeloma and Leukemia 23, S205, 2023 | | 2023 |
